𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle

✍ Scribed by Shai Yarkoni; Ayelet Kaminitz; Yuval Sagiv; Isaac Yaniv; Nadir Askenasy


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
453 KB
Volume
30
Category
Article
ISSN
0265-9247

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

A large body of evidence on the activity of regulatory T (Treg) cells was gathered during the last decade, and a similar number of reviews and opinion papers attempted to integrate the experimental findings. The abundant literature clearly delineates an exciting area of research but also underlines some major controversies. A linear cause–result interpretation of experimental maneuvers often ignores the fact that the activity of Treg cells is orchestrated with the effector T (Teff) cells within an intricate network of physiological immune homeostasis. Every modulation of the activity of the effector (cytotoxic) immune system revolves to affect the activity of regulatory (suppressive) cells through elaborate feedback loops of negative and positive regulation. The lack of IL‐2 production by innate Treg cells makes this cytokine a prime coupler of the effector and suppressive mechanisms. Here we attempt to integrate evidence that delineates the involvement of IL‐2 in primary and secondary feedback loops that regulate the activity of suppressive cells within the elaborate network of physiological immune homeostasis.Β©2007 Wiley Periodicals, Inc BioEssays 30:875–888, 2008. Β© 2008 Wiley Periodicals, Inc.


πŸ“œ SIMILAR VOLUMES


Expansion of regulatory T cells via IL-2
✍ Ruolan Liu; Qinghua Zhou; Antonio La Cava; Denise I. Campagnolo; Luc Van Kaer; F πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 635 KB

## Abstract Human autoimmune diseases are often characterized by a relative deficiency in CD4^+^CD25^+^ regulatory T cells (Treg). We therefore hypothesized that expansion of Treg can ameliorate autoimmune pathology. We tested this hypothesis in an experimental model for autoimmune myasthenia gravi

IL-2 induces in vivo suppression by CD4+
✍ Susan Brandenburg; Takeshi Takahashi; Maurus de la Rosa; Marko Janke; Gabriele K πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 403 KB

## Abstract Interleukin‐2 (IL‐2) treatment is currently used to enhance T cell‐mediated immune responses against tumors or in viral infections. At the same time, IL‐2 is essential for the peripheral homeostasis of CD4^+^CD25^+^Foxp3^+^ regulatory T cells (Treg). In our study, we show that IL‐2 is a